Journal of the National Comprehensive Cancer Network-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2185627, encodeId=c108218562e4c, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a18377469, createdName=ms3000001535095984, createdTime=Sat Feb 03 10:45:45 CST 2024, time=2024-02-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2154981, encodeId=a353215498101, content=Received/Under Preliminary Consideration 13天了不知道啥情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4b26155822, createdName=总是有一手, createdTime=Mon Aug 28 16:53:05 CST 2023, time=2023-08-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2152889, encodeId=51a9215288964, content=偏重的研究方向：队列研究;临床肿瘤研究 经验分享：历时4个月录取了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:50:17 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2152888, encodeId=1a5521528884d, content=3.31 投稿 6.08 一修回来 6.25 第一次修改返回去 8.14 二修晚上10点40分，审稿人要求删除其中几张多余的图片 8.15 凌晨5点文章接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:48:54 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1199004, encodeId=8cc0119900492, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床肿瘤研究;队列研究 经验分享：NCCN指南的官方杂志，肿瘤领域非常权威以后引用率也肯定高，只要idea够新能稍微改进现有的指南推荐就能得到快速发表，从投稿到接收不到2月，免版面费，但是接收至online一般得半年左右，感谢编辑的高效工作！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=瓜瓜guagua, createdTime=Thu Mar 03 10:33:07 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102348, encodeId=f8de210234878, content=偏重的研究方向：胃癌 经验分享：Received/Under Preliminary Consideration 6天，Under Consideration 1天，Under Review 1天，不知道是不是送外审了，还是在编辑手里，焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ff65539885, createdName=qj756412748, createdTime=Thu Nov 24 08:44:08 CST 2022, time=2022-11-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1104477, encodeId=a8d611044e7b5, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104478, encodeId=368111044e8d6, content=researcharticle和其它文章类型有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978460, encodeId=084e9e8460f3, content=双盲审稿，Received/Under Preliminary Consideration 6天没有动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Thu Jul 01 05:55:07 CST 2021, time=2021-07-01, status=1, ipAttribution=)]

2024-02-03 ms3000001535095984 来自北京

1

17 0

[GetPortalCommentsPageByObjectIdResponse(id=2185627, encodeId=c108218562e4c, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a18377469, createdName=ms3000001535095984, createdTime=Sat Feb 03 10:45:45 CST 2024, time=2024-02-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2154981, encodeId=a353215498101, content=Received/Under Preliminary Consideration 13天了不知道啥情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4b26155822, createdName=总是有一手, createdTime=Mon Aug 28 16:53:05 CST 2023, time=2023-08-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2152889, encodeId=51a9215288964, content=偏重的研究方向：队列研究;临床肿瘤研究 经验分享：历时4个月录取了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:50:17 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2152888, encodeId=1a5521528884d, content=3.31 投稿 6.08 一修回来 6.25 第一次修改返回去 8.14 二修晚上10点40分，审稿人要求删除其中几张多余的图片 8.15 凌晨5点文章接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:48:54 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1199004, encodeId=8cc0119900492, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床肿瘤研究;队列研究 经验分享：NCCN指南的官方杂志，肿瘤领域非常权威以后引用率也肯定高，只要idea够新能稍微改进现有的指南推荐就能得到快速发表，从投稿到接收不到2月，免版面费，但是接收至online一般得半年左右，感谢编辑的高效工作！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=瓜瓜guagua, createdTime=Thu Mar 03 10:33:07 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102348, encodeId=f8de210234878, content=偏重的研究方向：胃癌 经验分享：Received/Under Preliminary Consideration 6天，Under Consideration 1天，Under Review 1天，不知道是不是送外审了，还是在编辑手里，焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ff65539885, createdName=qj756412748, createdTime=Thu Nov 24 08:44:08 CST 2022, time=2022-11-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1104477, encodeId=a8d611044e7b5, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104478, encodeId=368111044e8d6, content=researcharticle和其它文章类型有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978460, encodeId=084e9e8460f3, content=双盲审稿，Received/Under Preliminary Consideration 6天没有动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Thu Jul 01 05:55:07 CST 2021, time=2021-07-01, status=1, ipAttribution=)]

2023-08-28 总是有一手来自安徽省

Received/Under Preliminary Consideration 13天了不知道啥情况了

32 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2185627, encodeId=c108218562e4c, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a18377469, createdName=ms3000001535095984, createdTime=Sat Feb 03 10:45:45 CST 2024, time=2024-02-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2154981, encodeId=a353215498101, content=Received/Under Preliminary Consideration 13天了不知道啥情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4b26155822, createdName=总是有一手, createdTime=Mon Aug 28 16:53:05 CST 2023, time=2023-08-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2152889, encodeId=51a9215288964, content=偏重的研究方向：队列研究;临床肿瘤研究 经验分享：历时4个月录取了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:50:17 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2152888, encodeId=1a5521528884d, content=3.31 投稿 6.08 一修回来 6.25 第一次修改返回去 8.14 二修晚上10点40分，审稿人要求删除其中几张多余的图片 8.15 凌晨5点文章接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:48:54 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1199004, encodeId=8cc0119900492, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床肿瘤研究;队列研究 经验分享：NCCN指南的官方杂志，肿瘤领域非常权威以后引用率也肯定高，只要idea够新能稍微改进现有的指南推荐就能得到快速发表，从投稿到接收不到2月，免版面费，但是接收至online一般得半年左右，感谢编辑的高效工作！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=瓜瓜guagua, createdTime=Thu Mar 03 10:33:07 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102348, encodeId=f8de210234878, content=偏重的研究方向：胃癌 经验分享：Received/Under Preliminary Consideration 6天，Under Consideration 1天，Under Review 1天，不知道是不是送外审了，还是在编辑手里，焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ff65539885, createdName=qj756412748, createdTime=Thu Nov 24 08:44:08 CST 2022, time=2022-11-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1104477, encodeId=a8d611044e7b5, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104478, encodeId=368111044e8d6, content=researcharticle和其它文章类型有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978460, encodeId=084e9e8460f3, content=双盲审稿，Received/Under Preliminary Consideration 6天没有动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Thu Jul 01 05:55:07 CST 2021, time=2021-07-01, status=1, ipAttribution=)]

2023-08-15 Mr.HHe 来自江西省

偏重的研究方向：队列研究;临床肿瘤研究
经验分享：历时4个月录取了

23 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2185627, encodeId=c108218562e4c, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a18377469, createdName=ms3000001535095984, createdTime=Sat Feb 03 10:45:45 CST 2024, time=2024-02-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2154981, encodeId=a353215498101, content=Received/Under Preliminary Consideration 13天了不知道啥情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4b26155822, createdName=总是有一手, createdTime=Mon Aug 28 16:53:05 CST 2023, time=2023-08-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2152889, encodeId=51a9215288964, content=偏重的研究方向：队列研究;临床肿瘤研究 经验分享：历时4个月录取了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:50:17 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2152888, encodeId=1a5521528884d, content=3.31 投稿 6.08 一修回来 6.25 第一次修改返回去 8.14 二修晚上10点40分，审稿人要求删除其中几张多余的图片 8.15 凌晨5点文章接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:48:54 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1199004, encodeId=8cc0119900492, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床肿瘤研究;队列研究 经验分享：NCCN指南的官方杂志，肿瘤领域非常权威以后引用率也肯定高，只要idea够新能稍微改进现有的指南推荐就能得到快速发表，从投稿到接收不到2月，免版面费，但是接收至online一般得半年左右，感谢编辑的高效工作！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=瓜瓜guagua, createdTime=Thu Mar 03 10:33:07 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102348, encodeId=f8de210234878, content=偏重的研究方向：胃癌 经验分享：Received/Under Preliminary Consideration 6天，Under Consideration 1天，Under Review 1天，不知道是不是送外审了，还是在编辑手里，焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ff65539885, createdName=qj756412748, createdTime=Thu Nov 24 08:44:08 CST 2022, time=2022-11-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1104477, encodeId=a8d611044e7b5, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104478, encodeId=368111044e8d6, content=researcharticle和其它文章类型有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978460, encodeId=084e9e8460f3, content=双盲审稿，Received/Under Preliminary Consideration 6天没有动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Thu Jul 01 05:55:07 CST 2021, time=2021-07-01, status=1, ipAttribution=)]

2023-08-15 Mr.HHe 来自江西省

3.31 投稿
6.08 一修回来
6.25 第一次修改返回去
8.14 二修晚上10点40分，审稿人要求删除其中几张多余的图片
8.15 凌晨5点文章接受

27 0

[GetPortalCommentsPageByObjectIdResponse(id=2185627, encodeId=c108218562e4c, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a18377469, createdName=ms3000001535095984, createdTime=Sat Feb 03 10:45:45 CST 2024, time=2024-02-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2154981, encodeId=a353215498101, content=Received/Under Preliminary Consideration 13天了不知道啥情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4b26155822, createdName=总是有一手, createdTime=Mon Aug 28 16:53:05 CST 2023, time=2023-08-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2152889, encodeId=51a9215288964, content=偏重的研究方向：队列研究;临床肿瘤研究 经验分享：历时4个月录取了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:50:17 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2152888, encodeId=1a5521528884d, content=3.31 投稿 6.08 一修回来 6.25 第一次修改返回去 8.14 二修晚上10点40分，审稿人要求删除其中几张多余的图片 8.15 凌晨5点文章接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:48:54 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1199004, encodeId=8cc0119900492, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床肿瘤研究;队列研究 经验分享：NCCN指南的官方杂志，肿瘤领域非常权威以后引用率也肯定高，只要idea够新能稍微改进现有的指南推荐就能得到快速发表，从投稿到接收不到2月，免版面费，但是接收至online一般得半年左右，感谢编辑的高效工作！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=瓜瓜guagua, createdTime=Thu Mar 03 10:33:07 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102348, encodeId=f8de210234878, content=偏重的研究方向：胃癌 经验分享：Received/Under Preliminary Consideration 6天，Under Consideration 1天，Under Review 1天，不知道是不是送外审了，还是在编辑手里，焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ff65539885, createdName=qj756412748, createdTime=Thu Nov 24 08:44:08 CST 2022, time=2022-11-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1104477, encodeId=a8d611044e7b5, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104478, encodeId=368111044e8d6, content=researcharticle和其它文章类型有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978460, encodeId=084e9e8460f3, content=双盲审稿，Received/Under Preliminary Consideration 6天没有动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Thu Jul 01 05:55:07 CST 2021, time=2021-07-01, status=1, ipAttribution=)]

2022-03-03 瓜瓜guagua

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：临床肿瘤研究;队列研究
经验分享：NCCN指南的官方杂志，肿瘤领域非常权威以后引用率也肯定高，只要idea够新能稍微改进现有的指南推荐就能得到快速发表，从投稿到接收不到2月，免版面费，但是接收至online一般得半年左右，感谢编辑的高效工作！

58 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2185627, encodeId=c108218562e4c, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a18377469, createdName=ms3000001535095984, createdTime=Sat Feb 03 10:45:45 CST 2024, time=2024-02-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2154981, encodeId=a353215498101, content=Received/Under Preliminary Consideration 13天了不知道啥情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4b26155822, createdName=总是有一手, createdTime=Mon Aug 28 16:53:05 CST 2023, time=2023-08-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2152889, encodeId=51a9215288964, content=偏重的研究方向：队列研究;临床肿瘤研究 经验分享：历时4个月录取了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:50:17 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2152888, encodeId=1a5521528884d, content=3.31 投稿 6.08 一修回来 6.25 第一次修改返回去 8.14 二修晚上10点40分，审稿人要求删除其中几张多余的图片 8.15 凌晨5点文章接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:48:54 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1199004, encodeId=8cc0119900492, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床肿瘤研究;队列研究 经验分享：NCCN指南的官方杂志，肿瘤领域非常权威以后引用率也肯定高，只要idea够新能稍微改进现有的指南推荐就能得到快速发表，从投稿到接收不到2月，免版面费，但是接收至online一般得半年左右，感谢编辑的高效工作！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=瓜瓜guagua, createdTime=Thu Mar 03 10:33:07 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102348, encodeId=f8de210234878, content=偏重的研究方向：胃癌 经验分享：Received/Under Preliminary Consideration 6天，Under Consideration 1天，Under Review 1天，不知道是不是送外审了，还是在编辑手里，焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ff65539885, createdName=qj756412748, createdTime=Thu Nov 24 08:44:08 CST 2022, time=2022-11-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1104477, encodeId=a8d611044e7b5, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104478, encodeId=368111044e8d6, content=researcharticle和其它文章类型有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978460, encodeId=084e9e8460f3, content=双盲审稿，Received/Under Preliminary Consideration 6天没有动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Thu Jul 01 05:55:07 CST 2021, time=2021-07-01, status=1, ipAttribution=)]

2022-11-24 qj756412748 来自浙江省

偏重的研究方向：胃癌
经验分享：Received/Under Preliminary Consideration 6天，Under Consideration 1天，Under Review 1天，不知道是不是送外审了，还是在编辑手里，焦急等待中

37 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2185627, encodeId=c108218562e4c, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a18377469, createdName=ms3000001535095984, createdTime=Sat Feb 03 10:45:45 CST 2024, time=2024-02-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2154981, encodeId=a353215498101, content=Received/Under Preliminary Consideration 13天了不知道啥情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4b26155822, createdName=总是有一手, createdTime=Mon Aug 28 16:53:05 CST 2023, time=2023-08-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2152889, encodeId=51a9215288964, content=偏重的研究方向：队列研究;临床肿瘤研究 经验分享：历时4个月录取了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:50:17 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2152888, encodeId=1a5521528884d, content=3.31 投稿 6.08 一修回来 6.25 第一次修改返回去 8.14 二修晚上10点40分，审稿人要求删除其中几张多余的图片 8.15 凌晨5点文章接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:48:54 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1199004, encodeId=8cc0119900492, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床肿瘤研究;队列研究 经验分享：NCCN指南的官方杂志，肿瘤领域非常权威以后引用率也肯定高，只要idea够新能稍微改进现有的指南推荐就能得到快速发表，从投稿到接收不到2月，免版面费，但是接收至online一般得半年左右，感谢编辑的高效工作！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=瓜瓜guagua, createdTime=Thu Mar 03 10:33:07 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102348, encodeId=f8de210234878, content=偏重的研究方向：胃癌 经验分享：Received/Under Preliminary Consideration 6天，Under Consideration 1天，Under Review 1天，不知道是不是送外审了，还是在编辑手里，焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ff65539885, createdName=qj756412748, createdTime=Thu Nov 24 08:44:08 CST 2022, time=2022-11-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1104477, encodeId=a8d611044e7b5, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104478, encodeId=368111044e8d6, content=researcharticle和其它文章类型有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978460, encodeId=084e9e8460f3, content=双盲审稿，Received/Under Preliminary Consideration 6天没有动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Thu Jul 01 05:55:07 CST 2021, time=2021-07-01, status=1, ipAttribution=)]

2021-12-29 ms6000000264964247

什么是Protocol？

60 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2185627, encodeId=c108218562e4c, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a18377469, createdName=ms3000001535095984, createdTime=Sat Feb 03 10:45:45 CST 2024, time=2024-02-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2154981, encodeId=a353215498101, content=Received/Under Preliminary Consideration 13天了不知道啥情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4b26155822, createdName=总是有一手, createdTime=Mon Aug 28 16:53:05 CST 2023, time=2023-08-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2152889, encodeId=51a9215288964, content=偏重的研究方向：队列研究;临床肿瘤研究 经验分享：历时4个月录取了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:50:17 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2152888, encodeId=1a5521528884d, content=3.31 投稿 6.08 一修回来 6.25 第一次修改返回去 8.14 二修晚上10点40分，审稿人要求删除其中几张多余的图片 8.15 凌晨5点文章接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:48:54 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1199004, encodeId=8cc0119900492, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床肿瘤研究;队列研究 经验分享：NCCN指南的官方杂志，肿瘤领域非常权威以后引用率也肯定高，只要idea够新能稍微改进现有的指南推荐就能得到快速发表，从投稿到接收不到2月，免版面费，但是接收至online一般得半年左右，感谢编辑的高效工作！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=瓜瓜guagua, createdTime=Thu Mar 03 10:33:07 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102348, encodeId=f8de210234878, content=偏重的研究方向：胃癌 经验分享：Received/Under Preliminary Consideration 6天，Under Consideration 1天，Under Review 1天，不知道是不是送外审了，还是在编辑手里，焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ff65539885, createdName=qj756412748, createdTime=Thu Nov 24 08:44:08 CST 2022, time=2022-11-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1104477, encodeId=a8d611044e7b5, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104478, encodeId=368111044e8d6, content=researcharticle和其它文章类型有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978460, encodeId=084e9e8460f3, content=双盲审稿，Received/Under Preliminary Consideration 6天没有动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Thu Jul 01 05:55:07 CST 2021, time=2021-07-01, status=1, ipAttribution=)]

2021-12-27 小动量

researcharticle和其它文章类型有什么区别？

65 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2185627, encodeId=c108218562e4c, content=1, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1a18377469, createdName=ms3000001535095984, createdTime=Sat Feb 03 10:45:45 CST 2024, time=2024-02-03, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2154981, encodeId=a353215498101, content=Received/Under Preliminary Consideration 13天了不知道啥情况了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4b26155822, createdName=总是有一手, createdTime=Mon Aug 28 16:53:05 CST 2023, time=2023-08-28, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2152889, encodeId=51a9215288964, content=偏重的研究方向：队列研究;临床肿瘤研究 经验分享：历时4个月录取了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:50:17 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2152888, encodeId=1a5521528884d, content=3.31 投稿 6.08 一修回来 6.25 第一次修改返回去 8.14 二修晚上10点40分，审稿人要求删除其中几张多余的图片 8.15 凌晨5点文章接受 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLYMz2ich9OKdOFmSZD7tqUnT5QTHUEqDwDxhWU0M6ediaYlVQ9IXkd2uJ6FAXVs4bZxtvGNKNIL8pQ/132, createdBy=84735270648, createdName=Mr.HHe, createdTime=Tue Aug 15 15:48:54 CST 2023, time=2023-08-15, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1199004, encodeId=8cc0119900492, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：临床肿瘤研究;队列研究 经验分享：NCCN指南的官方杂志，肿瘤领域非常权威以后引用率也肯定高，只要idea够新能稍微改进现有的指南推荐就能得到快速发表，从投稿到接收不到2月，免版面费，但是接收至online一般得半年左右，感谢编辑的高效工作！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=瓜瓜guagua, createdTime=Thu Mar 03 10:33:07 CST 2022, time=2022-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102348, encodeId=f8de210234878, content=偏重的研究方向：胃癌 经验分享：Received/Under Preliminary Consideration 6天，Under Consideration 1天，Under Review 1天，不知道是不是送外审了，还是在编辑手里，焦急等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ff65539885, createdName=qj756412748, createdTime=Thu Nov 24 08:44:08 CST 2022, time=2022-11-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1104477, encodeId=a8d611044e7b5, content=什么是Protocol？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104478, encodeId=368111044e8d6, content=researcharticle和其它文章类型有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:52 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=978460, encodeId=084e9e8460f3, content=双盲审稿，Received/Under Preliminary Consideration 6天没有动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Thu Jul 01 05:55:07 CST 2021, time=2021-07-01, status=1, ipAttribution=)]

2021-07-01 1dd96cb3m86(暂无匿称)

双盲审稿，Received/Under Preliminary Consideration 6天没有动静

72 14

展开14条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务